Christie Bartels is a Rheumatology/Immunology physician affiliated with University of Wisconsin–Madison. OpenAlex indexes 161 publications with 5,280 citations (h-index 36).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
451 Junction Rd
Madison, WI 537172656
Telephone
608-263-7577Provider last certified this registry record 26 Jan 2021.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
31.4%Folate Analog Metabolic Inhibitor8.3%Methotrexate84%Methotrexate Sodium16%Part D<11 patientsNonsteroidal Anti-inflammatory Drug5.7%Celecoxib100%Part D≥18 patients+ 7 more classes in this area
Nervous system
24.6%Gabapentinoids12.3%Pregabalin55%Gabapentin46%Part D≥14 patientsCholinergic Receptor Agonist4.8%Pilocarpine Hcl77%Cevimeline Hcl23%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
19.5%Corticosteroid9.5%Prednisone100%Part D≥31 patientsProton pump inhibitor7.9%Omeprazole81%Pantoprazole Sodium19%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2012–2015 per NIH RePORTER. The latest:
- Impact of Rheumatologist Communication Upon Managing Cardiovascular Risk in RA
University of Wisconsin-Madison
FY2015$756K23AR062381 - Impact of Rheumatologist Communication Upon Managing Cardiovascular Risk in RA
University of Wisconsin-Madison
FY2014$140,805K23AR062381 - Impact of Rheumatologist Communication Upon Managing Cardiovascular Risk in RA
University of Wisconsin-Madison
FY2013$140,805K23AR062381
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 2025 American College of Rheumatology ( <scp>ACR</scp> ) Guideline for the Treatment of Systemic Lupus Erythematosus
Arthritis Care & Research
2025 - Multimorbidity in Rheumatoid Arthritis: Literature Review and Future Directions
Current Rheumatology Reports
2023 - Disparities in 30‐day readmission rates among Medicare enrollees with dementia
Journal of the American Geriatrics Society
2023
Similar KOLs
Other experts from the same institution or the same specialty.
William Busse, MD
University of Wisconsin–Madison
David Andes, MD
University of Wisconsin–Madison
Neil Binkley, MD
University of Wisconsin–Madison
Robert Lemanske, MD
University of Wisconsin–Madison
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”